cas 38953-42-3|| where to buy 4-Amino-6-chloro-5-hydroxypyrimidine

Nombre del producto:4-Amino-6-chloro-5-hydroxypyrimidine

IUPAC Name:4-amino-6-chloropyrimidin-5-ol

Unidad de embalaje	Stock disponible	Precio($)
CM116619-100mg	in stock	ƥƿ
CM116619-250mg	in stock	ŗů
CM116619-1g	in stock	ľŹȃ
CM116619-5g	in stock	ƥŹŗ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 38953-42-3 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :38953-42-3; Fórmula molecular:C4H4ClN3O; Punto de fusión:-; Código de sonrisas:OC1=C(Cl)N=CN=C1N; Densidad:

: Número de catálogo:CM116619; Peso molecular:145.55; Punto de ebullición:312.5°C at 760 mmHg; Nº Mdl:MFCD13689013; Almacenamiento:Store at room temperature

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Remibrutinib; Novartis announced new positive data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib - a highly selective, oral Bruton's tyrosine kinase (BTK) inhibitor - in people with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines. In the studies, remibrutinib met all primary and secondary endpoints at Week 12. Remibrutinib is a potential 'best-in-class' BTK inhibitor. It can covalently bind to the BTK enzyme of B cells and myeloid cells. While strongly inhibiting BTK activity, it reduces the systemic exposure of the drug and reduces the risk of adverse events and drug interactions.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.